Athena Athena

X
[{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$330.0 million","newsHeadline":"Sandoz completes acquisition of Aspen\u2019s Japanese operations, strengthening its position in world\u2019s third largest market for generics and off-patent medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$757.2 million","upfrontCash":"$310.4 million","newsHeadline":"Divestment of Aspen\u2019s European Thrombosis Business to Mylan and Withdrawal of Cautionary","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Strategic Partnership with U.S-Based Avion Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Acino Pharma AG","pharmaFlowCategory":"D","amount":"$119.4 million","upfrontCash":"Undisclosed","newsHeadline":"Acino Acquires Selected Aspen Brands in South Africa","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm And Aspen Partner To Launch Prostate Cancer Drug Trelstar\u00ae In South Africa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes a Collaboration Agreement to Manufacture and Make Available Four Aspen-Branded Vaccines for Africa","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Gates Foundation","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen, CEPI And The Bill & Melinda Gates Foundation Expand Commitments To Improve Access To Vaccines In Africa","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia Registers First Eye Drops to Slow Short-sightedness Progress in Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$99.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Two Significant Agreements with Sandoz for China and Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Peptide","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Aspen API

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

            Lead Product(s): Octreotide Acetate

            Therapeutic Area: Endocrinology Product Name: Sandostatin LAR Depot

            Highest Development Status: Approved Product Type: Peptide

            Recipient: Sandoz B2B

            Deal Size: $99.9 million Upfront Cash: Undisclosed

            Deal Type: Agreement December 04, 2023

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            PNEUMOSIL® (pneumococcal polysaccharide conjugate vaccine – adsorbed, 10 Valent), a well-designed vaccine, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.

            Lead Product(s): Pneumococcal Polysaccharide Conjugate Vaccine

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Pneumosil

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Gates Foundation

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Funding December 12, 2022

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            PNEUMOSIL® (Pneumococcal Conjugate Vaccine – adsorbed, 10 Valent), a well-designed vaccine with relevant serotypes, provide comparable protection by targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries.

            Lead Product(s): 10 Valent Pneumococcal Polysaccharide Conjugate Vaccine

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Pneumosil

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Serum Institute of India

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 31, 2022

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            EIKANCE (atropine sulfate monohydrate eye drops) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and may be initiated in children when myopia progresses by 1 or more diopters per year.

            Lead Product(s): Atropine Sulfate

            Therapeutic Area: Ophthalmology Product Name: Eikance

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2022

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer patients in this region.

            Lead Product(s): Triptorelin Pamoate

            Therapeutic Area: Oncology Product Name: Trelstar

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Debiopharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 01, 2022

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.

            Lead Product(s): Ad26.COV2.S

            Therapeutic Area: Infections and Infectious Diseases Product Name: JNJ-78436735

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Johnson & Johnson

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 30, 2021

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.

            Lead Product(s): Esomeprazole Magnesium

            Therapeutic Area: Gastroenterology Product Name: Trustan

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Acino Pharma AG

            Deal Size: $119.4 million Upfront Cash: Undisclosed

            Deal Type: Acquisition October 22, 2021

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.

            Lead Product(s): Conjugated Estrogens

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cenestin

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Avion Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 12, 2020

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

            Lead Product(s): Fondaparinux Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Viatris

            Deal Size: $757.2 million Upfront Cash: $310.4 million

            Deal Type: Acquisition September 08, 2020

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            The acquisition strengthens Sandoz’s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan like Lidocaine Hydrochloride.

            Lead Product(s): Lidocaine Hydrochloride

            Therapeutic Area: Neurology Product Name: Lidocaine HCl-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sandoz B2B

            Deal Size: $440.0 million Upfront Cash: $330.0 million

            Deal Type: Acquisition January 31, 2020

            Aspen API Comapny Banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier
            Post Enquiry
            POST ENQUIRY